Sandwich ELISA, Biotin-labelled antibody
Serum, Plasma (EDTA, citrate, heparin)
At ambient temperature. Upon receipt, store the product at the temperature recommended below.
Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box)
- It is intended for research use only
- The total assay time is less than 5 hours
- The kit measures CHI3L1 in human serum and plasma (EDTA, citrate, heparin)
- Assay format is 96 wells
- Standard is a recombinant protein produced in NSO cells
- Components of the kit are provided ready to use, concentrated or lyophilized
Immune Response, Infection and Inflammation
Chitinase 3-like 1 (CHI3L1), also called cartilage glycoprotein 39 or YKL-40 in human and breast regression protein 39 in mice, is a 40 kDa chitin-binding glycoprotein without chitinase activity, and it has been shown to act as an important regulator of acute and chronic inflammation.
This molecule is synthesized under inflammatory conditions, including bronchial asthma, inflammatory bowel disease, and cancer, but is not highly expressed under physiological conditions. This glycoprotein is expressed and secreted by a variety of cell types including articular chondrocytes, synoviocytes, osteoblasts, macrophages, neutrophils, and epithelial cells.
Up to now, several studies have shown an important link between CHI3L1 and inflammation or metabolic diseases, including asthma, hypertension, diabetes mellitus, insulin resistance, and atherosclerosis, and naturally believe that CHI3L1 may be a potential biomarker and therapeutic target for the related diseases.
It is also highly regulated, being stimulated by a number of mediators including IL-13 and IFN-γ and being detected in exaggerated quantities in the circulation and or biologic fluids from patients with a spectrum of diseases including asthma, COPD, rheumatoid arthritis, cancer, diabetes, and atherosclerosis. YKL-40/Chi3l1 is elevated in the serum of patients with community-acquired pneumonia requiring hospitalizations, patients with cystic fibrosis and acute lung infections, and control subjects following endotoxin injection.